Methods and compositions for malic enzyme 2 (ME2) as a target for cancer therapy
AssigneeBeth Israel Deaconess Medical Center, Inc.
InventorsVikas P. Sukhatme, Jian-Guo Ren
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent.
Claims14
A method of treating or prophylactically treating a subject having cancer, said method comprising administering to said subject a malic enzyme 2 inhibitor in an amount sufficient to treat said cancer, wherein the malic enzyme 2 inhibitor is an RNAi agent or antisense oligonucleotide that comprises any one of SEQ ID NOs:1-36.
A method of treating or prophylactically treating a subject having cancer, said method comprising administering to said subject a malic enzyme 2 inhibitor comprising a nucleic acid sequence identical to the sequence of any one of SEQ ID NOs:1-36 in an amount sufficient to treat said cancer.
Dependencies are inferred from the claim text.